Armin Rashidi, University of Minnesota
Mehdi Hamadani, Medical College of Wisconsin; King Faisal Specialist Hospital Center and Research
Mei-Jie Zhang, Medical College of Wisconsin
Hai-Lin Wang, Medical College of Wisconsin
Hisham Abdel-Azim, University of Southern California
Mahmoud Aljurf, King Faisal Specialist Hospital Center and Research
Amer Assal, NYPH/Columbia University Medical Center; Sarah Cannon BMT Program
Ashish Bajel, Royal Melbourne Hospital City Campus
Asad Bashey, Northside Hospital, Atlanta
Minoo Battiwalla, Sarah Cannon BMT Program
Amer M. Beitinjaneh, University of Miami
Nelli Bejanyan, Moffitt Cancer Center
Vijaya Raj Bhatt, University of Nebraska Medical Center
Javier Bolaños-Meade, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Michael Byrne, Vanderbilt University Medical Center; Imperial College London
Jean-Yves Cahn, CHU Grenoble Alpes
Mitchell Cairo, New York Medical College
Stefan Ciurea, MD Anderson Cancer Center
Edward Copelan, Carolinas HealthCare System
Corey Cutler, Dana-Farber Cancer Institute
Andrew Daly, Tom Baker Cancer Center, Calgary
Miguel-Angel Diaz, Hospital Infantil Universitario Nino Jesus
Nosha Farhadfar, University of Florida College of Medicine
Robert P. Gale, University of Miami; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Imperial College London
Siddhartha Ganguly, University of Kansas
Michael R. Grunwald, Carolinas HealthCare System
Theresa Hahn, Roswell Park Cancer Institute
Shahrukh Hashmi, King Faisal Specialist Hospital Center and Research; Mayo Clinic
Gerhard C. Hildebrandt, Moffitt Cancer Center; University of Kentucky
H. Kent Holland, Northside Hospital, Atlanta
Nasheed Hossain, Loyola University Chicago
Christopher G Kanakry, National Cancer Institute, National Institutes of Health
Mohamed A. Kharfan-Dabaja, Mayo Clinic
Nandita Khera, Mayo Clinic
Yener Koc, Medical Park Hospital, Antalya, Turkey
Hillard M. Lazarus, Case Western Reserve University
Jong-Wook Lee, University of Nebraska Medical Center; Catholic University of Korea
Johan Maertens, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; University Hospital Gasthuisberg
Rodrigo Martino, Hospital de la Santa Creu i Sant Pau
Joseph McGuirk, CHU Grenoble Alpes; University of Kansas
Reinhold Munker, Louisiana State University Health Shreveport
Hemant S. Murthy, Dana-Farber Cancer Institute; University of Florida College of Medicine
Ryotaro Nakamura, City of Hope, Duarte, CA
Sunita Nathan, Rush University Medical Center
Taiga Nishihori, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; H. Lee Moffitt Cancer Center and Research Institute
Neil D. Palmisiano, Thomas Jefferson UniversityFollow
Sagar Patel, Moffitt Cancer Center; CHU Grenoble Alpes; Cleveland Clinic Foundation
Joseph Pidala, H. Lee Moffitt Cancer Center and Research Institute
Rebecca Olin, University of California San Francisco Medical Center
Richard F. Olsson, NYPH/Columbia University Medical Center; Karolinska Institutet; Uppsala University
Betul Oran, University of Texas MD Anderson Cancer Center
Olov Ringden, Karolinska Institutet
David Rizzieri, Duke University
Jacob Rowe, Shaare Zedek Medical Center
Mary Lynn Savoie, Tom Baker Cancer Center, Calgary
Kirk R. Schultz, British Columbia Children’s Hospital, University of British Columbia
Sachiko Seo, Dokkyo Medical University
Brian C. Shaffer, Memorial Sloan Kettering Cancer Center
Anurag Singh, University of Kansas
Melhem Solh, Northside Hospital, Atlanta
Keith Stockerl-Goldstein, Barnes Jewish Hospital, St. Louis
Leo F. Verdonck, Isala Clinic, Zwolle
John Wagner, Thomas Jefferson UniversityFollow
Edmund K. Waller, CHU Grenoble Alpes; Emory University
Marcos De Lima, University Hospitals Case Medical Center
Brenda M. Sandmaier, University of Washington
Mark Litzow, Mayo Clinic Rocheste
Dan Weisdorf, University of Minnesota Medical Center
Rizwan Romee, Dana-Farber Cancer Institute; National Cancer Institute, National Institutes of Health; Dana-Farber Cancer Institute, Harvard Medical School
Wael Saber, Medical College of Wisconsin

Document Type


Publication Date



This article has been peer reviewed. It is the author’s final published version in Blood Advances, Volume 3, Issue 12, June 2019, Pages 1826-1836.

The published version is available at Copyright © American Society of Hematology


HLA-haploidentical hematopoietic cell transplantation (Haplo-HCT) using posttransplantation cyclophosphamide (PT-Cy) has improved donor availability. However, a matched sibling donor (MSD) is still considered the optimal donor. Using the Center for International Blood and Marrow Transplant Research database, we compared outcomes after Haplo-HCT vs MSD in patients with acute myeloid leukemia (AML) in first complete remission (CR1). Data from 1205 adult CR1 AML patients (2008-2015) were analyzed. A total of 336 patients underwent PT-Cy–based Haplo-HCT and 869 underwent MSD using calcineurin inhibitor–based graft-versus-host disease (GVHD) prophylaxis. The Haplo-HCT group included more reduced-intensity conditioning (65% vs 30%) and bone marrow grafts (62% vs 7%), consistent with current practice. In multivariable analysis, Haplo-HCT and MSD groups were not different with regard to overall survival (P 5 .15), leukemia-free survival (P 5 .50), nonrelapse mortality (P 5 .16), relapse (P 5 .90), or grade II-IV acute GVHD (P 5 .98). However, the Haplo-HCT group had a significantly lower rate of chronic GVHD (hazard ratio, 0.38; 95% confidence interval, 0.30-0.48; P, .001). Results of subgroup analyses by conditioning intensity and graft source suggested that the reduced incidence of chronic GVHD in Haplo-HCT is not limited to a specific graft source or conditioning intensity. Center effect and minimal residual disease–donor type interaction were not predictors of outcome. Our results indicate a lower rate of chronic GVHD after PT-Cy–based Haplo-HCT vs MSD using calcineurin inhibitor–based GVHD prophylaxis, but similar other outcomes, in patients with AML in CR1. Haplo-HCT is a viable alternative to MSD in these patients. © 2019 American Society of Hematology. All rights reserved.

PubMed ID




Included in

Oncology Commons